Tovorafenib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tovorafenib. Educational only — not medical advice.
Labeled uses
OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: FDA labeling via NIH DailyMed (set ea3a9631…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.